Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1475.69% is 59% above its 4-year average of -3608.23%, near the high end of its 4-year range (-17951.47%–-113.82%).
5.96% above its 12-month average of -1569.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -113.82%.
EBITDA MARGIN
-1475.69%
EBITDA MARGIN AVG TTM
-1569.14%
EBITDA MARGIN AVG 3Y
-1310.83%
EBITDA MARGIN AVG 5Y
-3608.23%
EBITDA MARGIN AVG 10Y
-2016.17%
EBITDA MARGIN AVG 15Y
-1384.68%
EBITDA MARGIN AVG 20Y
-1557.43%
CURRENT VS TTM AVG
+5.96%
CURRENT VS 3Y AVG
-12.58%
CURRENT VS 5Y AVG
+59.10%
CURRENT VS 10Y AVG
+26.81%
CURRENT VS 15Y AVG
-6.57%
CURRENT VS 20Y AVG
+5.25%
Abeona Therapeutics Inc.
Market Cap
$279.56M
EBITDA Margin
-1475.69%
TTM Avg
-1569.14%
3Y Avg
-1310.83%
5Y Avg
-3608.23%
Market Cap
$281.16M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
Market Cap
$286.94M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$275.95M
EBITDA Margin
-13.37%
TTM Avg
-2.68%
3Y Avg
-19.85%
5Y Avg
-36.16%
Market Cap
$272.91M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.17M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
Market Cap
$292.07M
EBITDA Margin
-101.16%
TTM Avg
-95.97%
3Y Avg
-88.25%
5Y Avg
-69.69%
Market Cap
$259.30M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $279.56M | -1475.69% | -1569.14% | -1310.83% | -3608.23% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $285.16M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -13.37% | -2.68% | -19.85% | -36.16% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| Standard BioTools Inc. (LAB)vs › | $292.07M | -101.16% | -95.97% | -88.25% | -69.69% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $258.48M | -768.62% | -551.06% | -374.75% | -290.29% |
Gross Margin
73.7%
EBITDA Margin
-1475.7%
Operating Margin
-1536.9%
Net Margin
-246.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -113.82% |
| 2026-03-31 | -254.17% |
| 2025-12-31 | -402.56% |
| 2025-06-30 | -5506.00% |
| 2023-06-30 | -277.60% |
| 2022-12-31 | -17951.47% |
| 2022-06-30 | -723.50% |
| 2022-03-31 | -5716.76% |
| 2021-12-31 | -1528.17% |
| 2020-12-31 | -445.90% |
| 2020-09-30 | -77.16% |
| 2018-12-31 | 903.62% |
| 2018-09-30 | -960.27% |
| 2018-06-30 | -4444.57% |
| 2018-03-31 | -1979.10% |
| 2017-12-31 | -4001.86% |
| 2017-09-30 | -2385.39% |
| 2017-06-30 | -3794.01% |
| 2017-03-31 | -2706.45% |
| 2016-12-31 | -2181.25% |
| 2016-09-30 | -2691.30% |
| 2016-06-30 | -3053.27% |
| 2016-03-31 | -2547.23% |
| 2015-12-31 | -2838.60% |
| 2015-09-30 | -2109.82% |
| 2015-06-30 | -1416.67% |
| 2015-03-31 | -730.23% |
| 2014-12-31 | -195.73% |
| 2014-09-30 | -267.80% |
| 2014-06-30 | -284.21% |
| 2014-03-31 | -634.62% |
| 2013-12-31 | -421.60% |
| 2013-09-30 | -367.72% |
| 2013-06-30 | -197.22% |
| 2013-03-31 | -41.01% |
| 2012-12-31 | -88.57% |
| 2012-09-30 | -107.69% |
| 2012-06-30 | -207.68% |
| 2012-03-31 | -34.23% |
| 2011-12-31 | -322.73% |
| 2011-09-30 | -165.99% |
| 2011-06-30 | -1452.98% |
| 2011-03-31 | -1392.00% |
| 2010-12-31 | -1237.41% |
| 2010-09-30 | -1761.42% |
| 2010-06-30 | -1791.43% |
| 2010-03-31 | -1550.98% |
| 2009-12-31 | -1560.58% |
| 2009-09-30 | -2736065.97% |
| 2009-06-30 | -3215.87% |
| 2009-03-31 | -4617.07% |
| 2008-12-31 | -1890.54% |
| 2008-09-30 | -7993.62% |
| 2008-06-30 | -1583.33% |
| 2008-03-31 | -27621.05% |
| 2007-12-31 | -3613.73% |
| 2007-09-30 | -26500.00% |
| 2005-12-31 | 293.76% |
| 2005-09-30 | -358.23% |
| 2005-06-30 | -879.52% |
| 2005-03-31 | -690.97% |
| 2004-12-31 | -815.94% |
| 2004-09-30 | -1071.89% |
| 2004-06-30 | -2851.47% |
| 2004-03-31 | -9145.00% |
| 2003-12-31 | -1028.37% |
| 2003-09-30 | -15600.00% |
| 2003-06-30 | -216.25% |
| 2003-03-31 | -504.58% |
| 2002-12-31 | -285.52% |
| 2002-09-30 | -2723.08% |
